FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366608910> ?p ?o ?g. }

• W4366608910 endingPage "640" @default.
• W4366608910 startingPage "626" @default.
• W4366608910 abstract "Macrophages represent the most prevalent immune cells in the tumor micro-environment, making them an appealing target for tumor immunotherapy. One of our previous studies showed that hydroxyapatite nanoparticles (HANPs) enhanced Toll-like receptor 4 (TLR4) signal transduction in macrophages. This study was proposed to investigate how HANPs manipulated the phenotype and function of macrophage against 4T1 breast tumors in the presence or absence of MPLA, a low toxic Toll-like receptor 4 (TLR4) agonist. The results demonstrated that the addition of HANPs to MPLA significantly promoted cytokine secretion and macrophage polarization toward a tumoricidal M1 phenotype. Further, the resulting supernatant from HANPs/MPLA co-stimulated macrophages enhanced 4T1 tumor cells apoptosis compared to that from macrophages treated with a single component or PBS control. In particular, we found HANPs elicited immunogenic cell death (ICD) indicated by the increased expression of danger signals, including HMGB1, CRT and ATP in 4T1 cells. Subsequently, the ICD derivatives-containing supernatant from HANPs-treated 4T1 cells activated macrophage and shifted the phenotype of the cells toward M1 type. Moreover, in a tumor-bearing mice model, HANPs and MPLA synergistically delayed tumor growth compared to PBS control, which was positively associated with the promoted macrophage polarization and ICD induction. Therefore, our findings demonstrated a potential platform to modulate the function of macrophages, and shed a new insight into the mechanism involving the immunomodulatory effect of HANPs for tumor therapy. STATEMENT OF SIGNIFICANCE: Polarizing macrophage toward tumoricidal phenotype by harnessing Toll-like receptor (TLR) agonists has been proven effective for tumor immunotherapy. However, the immunomodulatory potency of TLR agonists is limited due to immune suppression or tolerance associated with TLR activation in immune cells. Herein, we introduced hydroxyapatite nanoparticles (HANPs) to MPLA, a TLR4 agonist. The results demonstrated that the addition of HANPs to MPLA promoted macrophage shift toward tumoricidal M1 phenotype, supported a hot tumor transformation, and delayed 4T1 tumor growth. Moreover, we found that HANPs elicited immunogenic cell death that produced danger signals from cancer cells thereby further facilitated macrophage polarization. This work is significant to direct the rational design of HANPs coupled with or without TLR agonists for tumor immunotherapy." @default.
• W4366608910 created "2023-04-23" @default.
• W4366608910 creator A5011299026 @default.
• W4366608910 creator A5018233815 @default.
• W4366608910 creator A5028703521 @default.
• W4366608910 creator A5038164303 @default.
• W4366608910 creator A5043804172 @default.
• W4366608910 creator A5044400826 @default.
• W4366608910 creator A5050407938 @default.
• W4366608910 creator A5061113674 @default.
• W4366608910 creator A5090998948 @default.
• W4366608910 creator A5091791565 @default.
• W4366608910 date "2023-07-01" @default.
• W4366608910 modified "2023-10-15" @default.
• W4366608910 title "Hydroxyapatite nanoparticles promote TLR4 agonist-mediated anti-tumor immunity through synergically enhanced macrophage polarization" @default.
• W4366608910 cites W1779771004 @default.
• W4366608910 cites W1965130745 @default.
• W4366608910 cites W1965178593 @default.
• W4366608910 cites W1987979026 @default.
• W4366608910 cites W1996213381 @default.
• W4366608910 cites W2021736304 @default.
• W4366608910 cites W2067632426 @default.
• W4366608910 cites W2081796577 @default.
• W4366608910 cites W2103582672 @default.
• W4366608910 cites W2109483577 @default.
• W4366608910 cites W2315436712 @default.
• W4366608910 cites W2346529982 @default.
• W4366608910 cites W2560836545 @default.
• W4366608910 cites W2595092778 @default.
• W4366608910 cites W2595265189 @default.
• W4366608910 cites W2753782603 @default.
• W4366608910 cites W2768527478 @default.
• W4366608910 cites W2784042879 @default.
• W4366608910 cites W2804669050 @default.
• W4366608910 cites W2834234275 @default.
• W4366608910 cites W2884787683 @default.
• W4366608910 cites W2885957766 @default.
• W4366608910 cites W2910190865 @default.
• W4366608910 cites W2930388365 @default.
• W4366608910 cites W2947122999 @default.
• W4366608910 cites W2947646427 @default.
• W4366608910 cites W2962961007 @default.
• W4366608910 cites W2965089489 @default.
• W4366608910 cites W2966791866 @default.
• W4366608910 cites W3011642937 @default.
• W4366608910 cites W3039655065 @default.
• W4366608910 cites W3047618013 @default.
• W4366608910 cites W3085553590 @default.
• W4366608910 cites W3104085757 @default.
• W4366608910 cites W3108774824 @default.
• W4366608910 cites W3125489602 @default.
• W4366608910 cites W3197196598 @default.
• W4366608910 cites W3198525580 @default.
• W4366608910 cites W3201599198 @default.
• W4366608910 cites W4225287625 @default.
• W4366608910 cites W4226044235 @default.
• W4366608910 cites W4293230850 @default.
• W4366608910 cites W4293749399 @default.
• W4366608910 doi "https://doi.org/10.1016/j.actbio.2023.04.027" @default.
• W4366608910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37086827" @default.
• W4366608910 hasPublicationYear "2023" @default.
• W4366608910 type Work @default.
• W4366608910 citedByCount "1" @default.
• W4366608910 crossrefType "journal-article" @default.
• W4366608910 hasAuthorship W4366608910A5011299026 @default.
• W4366608910 hasAuthorship W4366608910A5018233815 @default.
• W4366608910 hasAuthorship W4366608910A5028703521 @default.
• W4366608910 hasAuthorship W4366608910A5038164303 @default.
• W4366608910 hasAuthorship W4366608910A5043804172 @default.
• W4366608910 hasAuthorship W4366608910A5044400826 @default.
• W4366608910 hasAuthorship W4366608910A5050407938 @default.
• W4366608910 hasAuthorship W4366608910A5061113674 @default.
• W4366608910 hasAuthorship W4366608910A5090998948 @default.
• W4366608910 hasAuthorship W4366608910A5091791565 @default.
• W4366608910 hasConcept C136449434 @default.
• W4366608910 hasConcept C153911025 @default.
• W4366608910 hasConcept C170493617 @default.
• W4366608910 hasConcept C192562407 @default.
• W4366608910 hasConcept C202751555 @default.
• W4366608910 hasConcept C203014093 @default.
• W4366608910 hasConcept C2776070231 @default.
• W4366608910 hasConcept C2776682551 @default.
• W4366608910 hasConcept C2776709828 @default.
• W4366608910 hasConcept C2777701055 @default.
• W4366608910 hasConcept C2779244956 @default.
• W4366608910 hasConcept C502942594 @default.
• W4366608910 hasConcept C55493867 @default.
• W4366608910 hasConcept C7244527 @default.
• W4366608910 hasConcept C86803240 @default.
• W4366608910 hasConcept C8891405 @default.
• W4366608910 hasConcept C95444343 @default.
• W4366608910 hasConceptScore W4366608910C136449434 @default.
• W4366608910 hasConceptScore W4366608910C153911025 @default.
• W4366608910 hasConceptScore W4366608910C170493617 @default.
• W4366608910 hasConceptScore W4366608910C192562407 @default.
• W4366608910 hasConceptScore W4366608910C202751555 @default.
• W4366608910 hasConceptScore W4366608910C203014093 @default.
• W4366608910 hasConceptScore W4366608910C2776070231 @default.

• next